Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05415137 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
A Phase 3 study of Pulmonary Sarcoidosis, sponsored by aTyr Pharma.
- Active
- Registry status
- Phase 3
- Development phase
- 268
- Enrollment target
- 20
- Study locations
NCT05415137: Active Phase 3 study of Pulmonary Sarcoidosis, sponsored by aTyr Pharma.
NCT05415137 is a Phase 3 study of Pulmonary Sarcoidosis that is active but no longer recruiting, run by aTyr Pharma. The registered enrollment target is 268 participants, below the 761-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05415137, a Phase 3 study of Pulmonary Sarcoidosis, is active but no longer recruiting, sponsored by aTyr Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 268 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Efzofitimod 3 mg/kg
- DRUG Efzofitimod 5 mg/kg
Study Locations (20)
Florida
- aTyr Investigative Site - Gainesville
- aTyr Investigative Site - Tampa
- aTyr Investigative Site - Weston
California
- aTyr Investigative Site - Los Angeles
- aTyr Investigative Site - Sacramento
Illinois
- aTyr Investigative Site - Chicago
- aTyr Investigative Site - Chicago
Michigan
- aTyr Investigative Site - Ada
- aTyr Investigative Site - Detroit
Minnesota
- aTyr Investigative Site - Minneapolis
- aTyr Investigative Site - Rochester
Alabama
- aTyr Investigative Site - Birmingham
Arizona
- aTyr Investigative Site - Phoenix
Colorado
- aTyr Investigative Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 3 |
What the registry record for NCT05415137 still lists
NCT05415137 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, below the 761-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Pulmonary Sarcoidosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05415137 names 20 study sites across 14 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT05415137 about?
NCT05415137 is a clinical study titled "Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis". This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving sta...
What is the current status of trial NCT05415137?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 268 participants. The study started on 2022-09-15. Estimated completion is 2025-08-31.
What conditions does trial NCT05415137 study?
This clinical trial studies the following conditions: Pulmonary Sarcoidosis.
What interventions are being tested in trial NCT05415137?
The interventions under investigation include: Placebo (DRUG), Efzofitimod 3 mg/kg (DRUG), Efzofitimod 5 mg/kg (DRUG).
Who is sponsoring clinical trial NCT05415137?
This trial is sponsored by aTyr Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05415137 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
RECRUITING · Phase 1
-
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
RECRUITING · Phase 2
-
Role of Genetic Factors in the Development of Lung Disease
RECRUITING
-
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
COMPLETED · NA
-
Treatment of Pulmonary Sarcoidosis With Pentoxifylline
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI